Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baozhu Keli in Ovarian Aging
NCT06256783Phase 1Recruiting
- Sponsor
- Tongji Hospital
- Start
- Aug 2022
- Primary completion
- Jan 2024
- Modality
- Implantable Devices, Transdermal Patches, Inhalation Devices
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Baozhu Keli in ovarian aging, sponsored by Tongji Hospital. Primary endpoint: Recovery rate of ovarian function at 6 months. Started Aug 2022; status: recruiting.
02
Drugs
Baozhu Keli
03
Conditions
ovarian aging
Beyond the preview
Go deeper on NCT06256783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06256783.